BioCentury
ARTICLE | Financial News

pSivida planning follow-on

July 19, 2013 12:18 AM UTC

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) proposed a follow-on late Thursday underwritten by Ladenburg Thalmann and MLV. pSivida's Iluvien fluocinolone acetonide invitreal implant is approved in Austria, Portugal, the U.K., France and Germany to treat chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. The injectable insert delivering fluocinolone acetonide (FA) to the retina is under review in the U.S. to treat chronic DME, with an Oct. 17 PDUFA date. Alimera Sciences Inc. (NASDAQ:ALIM) has rights to the product from pSivida, which also has two FDA-approved Orphan ophthalmic products partnered with and marketed by Bausch + Lomb Inc. (Rochester, N.Y.). ...